该项目是探讨预防性阿那白滞素在靶向CD19的CAR-T细胞治疗复发难治大B细胞淋巴瘤和套细胞淋巴瘤患者中的疗效的2期临床试验。初步结果表明,在接受靶向CD19的CAR-T细胞治疗的淋巴瘤患者中,预防性阿那白滞素可降低ICANS发生率。 靶向C...
[3] Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial. Retrieved December 11, 2023, from https://www.globenewswire.com/news-release/2023/12/09/2793436/0/en/Corvus-Pharmaceuticals-Presents-New-Interim-Soquelitinib-Data-from-its-Phase-1-...
4. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy 译：动态监测循环肿瘤DNA 揭示接受 CAR T 细胞治疗的复发或难治性大 B 细胞淋巴瘤患者的结果和基因组变化 作者列表:Zou H;L...
Kamdar M, Solomon SR, Arnason J, et al; TRANSFORM Investigators. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with...
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023.https://doi.org/10.1038/s41591-023-02404-6
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023. https://doi.org/10.1038/s41591-023-02404-6 ...
想寻求CAR-T疗法帮助或参与临床试验获得天价疗法免费治疗机会的患者，可将治疗经历、近期影像学及病理检查结果等，提交至医学部，进行初步评估!参考资料 [1]Neelapu S S,et al.Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial[J]. Nature ...
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023. https:///10.1038/s41591-023-02404-6 [2].Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell...
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023. https://doi.org/10.1038/s41591-023-02404-6 ...
这一发现表明这种“双靶点”方法在开发有效、持久的实体瘤(如GBM)疗法方面迈出了令人鼓舞的一步。相关研究结果于2024年3月13日在线发表在Nature Medicine期刊上,论文标题为“Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results” ...